BACTIGUARD HOLDING AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.6 SEK | +1.16% |
|
+2.35% | +12.62% |
| Apr. 25 | Transcript : Bactiguard Holding AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Bactiguard Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +12.62% | 220M | C- | ||
| +11.48% | 27.79B | B+ | ||
| -31.67% | 2.98B | B- | ||
| -15.97% | 2.52B | C+ | ||
| +11.90% | 2.34B | - | A- | |
| -1.11% | 1.91B | B | ||
| -7.78% | 1.39B | B | ||
| -0.38% | 1.27B | - | ||
| +3.58% | 1.13B | - | ||
| +13.51% | 1.12B | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BACTI B Stock
- Ratings Bactiguard Holding AB
